MHRAsafety guidance72% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Alexion Pharmaceuticals, Inc..
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Nephrology · Monoclonal Antibody
- Sub-indication
- General
Related signal: Ravulizumab Shows Promise in Reducing Delayed Graft Function in Kidney Transplant Patients